Biotech RadarJobs updated

COMPANY

Indapta Therapeutics

HQ: Houston, TX source · indapta.com ↗ · West Coast

Clinical Phase 2

Keywords: oncology immunology cell therapy cancer autoimmune diseases Multiple Myeloma NHL Blood Cancer Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory Multiple Myeloma Relapsed Multiple Myeloma Multiple Sclerosis Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis Non-Active Secondary Progressive Multiple Sclerosis Non-Active SPMS Autoimmune Diseases of the Nervous System Nervous System Diseases Demyelinating Diseases Immune System Diseases Demyelinating Autoimmune Diseases, Central Nervous System (CNS) IDP-023

Location: Houston, TX · source · Oct 14, 2025

Profile checked Oct 10, 2026

2Trials (company is sponsor)2NIH grants

Timeline

  1. Trial start Phase 1: IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis source ↗
  2. Trial start Phase 1/Phase 2: IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers source ↗

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06119685IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersPhase 1/Phase 2RecruitingOct 25, 2023Dec 30, 2025 (estimated)
NCT06677710IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisPhase 1SuspendedJun 30, 2026Dec 31, 2026 (estimated)

NIH awards 2

Annual award amounts. Total $600K.

Feedback